Effect of rosuvastatin on risk markers for venous thromboembolism in cancer.
Ades S, Douce D, Holmes CE, Cory S, Prior S, Butenas S, Callas P, Cushman M.
Ades S, et al. Among authors: prior s.
J Thromb Haemost. 2018 Jun;16(6):1099-1106. doi: 10.1111/jth.14004. Epub 2018 Apr 29.
J Thromb Haemost. 2018.
PMID: 29575637
Free article.
Clinical Trial.
Patients/Methods This double-blind, crossover, randomized controlled trial among patients with advanced cancer receiving systemic therapy allocated participants to rosuvastatin 20 mg daily or placebo for 3-4 weeks prior to crossover to the alternative therapy, with a 3-5-w …
Patients/Methods This double-blind, crossover, randomized controlled trial among patients with advanced cancer receiving systemic therapy al …